FPH Confirms Status as Essential Service

Stock Exchange Announcement
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare confirms status as essential service

Auckland, New Zealand, 23 March 2020 – Following the announcement today by New Zealand’s
Prime Minister that the COVID-19 alert status will be raised to Level 4 in 48 hours time, Fisher &
Paykel Healthcare Corporation Limited advises that it has been designated an essential service by
the New Zealand Government and will continue operations in its Auckland facilities.

“As we advised last week, we have ramped up our manufacturing output and this will continue
under the Level 4 alert status. As an essential service, we are continuing to focus on meeting
the global demand for our respiratory products that are directly involved in treating patients with
COVID-19,” said Managing Director and CEO Lewis Gradon.

“We are very appreciative of the support that we have received from our suppliers to date. We ask
them to continue to work with us, as essential suppliers of raw materials, components, logistics and
other services that are directly required for us to manufacture and supply critical respiratory
products.

“We have already enabled remote working for our employees who are not directly critical to our
manufacturing and supply operations. This has reduced the number of people in our offices,
cafeterias and other common spaces. Our aim is to create a work environment that is as safe as
possible for the people whose jobs require being on site. We have already implemented extra
cleaning and sanitisation measures and social distancing protocols.

“This is a rapidly changing situation. We are monitoring any developments closely and will
proactively share further updates as we are able. I want to again acknowledge the tireless
efforts of our people all around the world during this challenging time,” said Mr Gradon.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com.

Ends

Media & Investor Contacts:
Karen Knott
Senior Communications Manager
karen.knott@fphcare.co.nz
+64 (0) 21 713 911
Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073


Authorised by:
Marcus Driller
VP Corporate & Company Secretary.